ARK Invest’s Cathie Wood Identifies Two Promising Biotech Stocks for Aggressive Investors\n\nARK Invest’s Cathie Wood has been making waves in the investment world with her thematic exchange-traded funds (ETFs) that focus on disruptive innovation in various sectors. While these funds have seen impressive returns, they also come with high expenses and volatility. For investors looking for new ideas without the high fees, ARK Invest’s funds can be a valuable resource. In particular, two biotech stocks owned by Wood, Ginkgo Bioworks Holdings (NYSE:DNA) and Recursion Pharmaceuticals (NASDAQ:RXRX), are worth considering for aggressive investors.\n\nGinkgo Bioworks is a leader in the field of synthetic biology, providing a platform for the creation of biologically based products. The company has recently expanded its presence in the pharmaceutical research and development space through partnerships with major players like Pfizer and Google Cloud. While Ginkgo’s stock has seen a significant decline since its IPO, the potential in its addressable markets is enormous. \n\nOn the other hand, Recursion Pharmaceuticals is using cutting-edge technology, such as AI and machine learning, to accelerate the drug discovery process. The company has formed partnerships with Nvidia and Tempus to enhance its unique techbio platform, which focuses on high-value areas like oncology.

ARKK), has delivered impressive returns over the past five years, driven by the tech boom. Woods' ETFs took a hit last year amid the tech rout.\n\nBritish chipmaker Arm Holdings plc's public debut was one of the most talked-about events on Wall Street last month, signaling a comeback in the IPO space. The stock rose by 25% during the first trading session, rejuvenating hopes for a resurgence of startup IPOs. But the momentum fizzled soon after, with the stock plummeting sharply since then. Woods, whose portfolios are concentrated on disruptive tech stocks, seems to have avoided the hype surrounding Arm's IPO.\n\n"As far as Arm, I think there might be a little bit too much emphasis on AI (artificial intelligence) when it comes to Arm and maybe not enough focus on the competitive dynamics out there," Wood said. "So we did not participate in that IPO, and we also compare it to the stocks in our portfolios. Arm came out, we think, from a valuation point of view, on the high side, and we see within our portfolios much lower-priced names with much more exposure to AI."\n\nWood believes that the hype surrounding AI is justified, as "innovation is undervalued given the enormous opportunities that we see ahead, catalyzed very importantly by artificial intelligence." Arm stock seems to have a tough time maintaining its prowess on Wall Street, facing stiff competition and macroeconomic headwinds.\n\nAs the tech sector rebounds, Woods' portfolio has been showing promise, as reflected by Ark Innovation ETF's 25% surge so far this year. Top holdings in the ARKK ETF include Tesla incorporated, Shopify incorporated, UiPath, Unity, Zoom Video Communications incorporated, Twilio, Coinbase Global incorporated, Roku incorporated, Block incorporated, and DraftKings. With inflation receding and the Fed signaling a more accommodative stance, Woods' ETFs are expected to continue their impressive run.\n\n Cathie Wood's ARK Invest has been a top performer in the tech sector, driven by its focus on disruptive tech stocks and AI.'